Skip to content
Bringing Nanoscience to Life
BlueWillow is safely harnessing nanotechnology to develop intranasal vaccines for challenging respiratory and sexually transmitted infections and intranasal immunotherapy (INIT) for food allergies.
Our intranasal vaccines elicit both systemic and mucosal immune responses. These two “layers” of immunity increase protection against some of the most challenging respiratory and sexually transmitted diseases.
Our intranasal immunotherapy (INIT) elicits mucosal immunity in the respiratory and gastrointestinal tracts where allergens enter the body. BlueWillow’s INIT products reprogram pre-existing allergic immunity to enable the long-term prevention of allergic reactions.
BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose.
In addition to the company’s lead NanoBio® Protect product, BlueWillow Biologics is developing its proprietary NanoVax® platform to enable intranasal vaccines for challenging respiratory & sexually transmitted infections and intranasal immunotherapy (INIT) for food & respiratory allergies. The company’s lead candidates include intranasal vaccines for influenza, anthrax, RSV and HSV-2, and intranasal immunotherapy for peanut and milk allergy. The company’s NanoVax® technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines and immunotherapy that elicit mucosal and systemic Th1/Th17 immunity. The NanoVax® platform uniquely elicits mucosal antibodies that serve as “bouncers at the door” as the body’s first line of defense against infections and allergens.
Recent BlueWillow News
-
11.10.20
-
8.21.20
-
5.22.20
-
5.6.20
-
4.22.20
Vaccine Pipeline
BlueWillow’s intranasal vaccine platform has successfully demonstrated safety and immunogenicity in humans with a seasonal flu vaccine, and safety and efficacy in primary animal models for several other diseases. In 2020, BlueWillow will initiate Phase 1 human studies for two intranasal vaccine programs — pandemic flu and anthrax — both of which will be funded by NIH.
The company has also demonstrated that it’s nanotechnology platform can be used to develop intranasal immunotherapy (INIT) for food and respiratory allergies. In 2019, BlueWillow received an SBIR Fast-Track contract to develop intranasal immunotherapy for peanut allergy. To date, BlueWillow’s INIT product has been shown to (i) induce mucosal immune responses in the gastrointestinal tract, (ii) elicit a Th2 to Th1 shift, (iii) suppress IgE antibody production and (iv) prevent inflammatory allergic responses upon subsequent exposure to peanut allergen.
Choose a program below and click for details on our research results and partnering information.
